ClinicalTrials.gg
RecruitingNCT05583617PLYCOMUpdated Nov 5, 2026

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

A Phase 1/2 interventional study of Cevostamab and Lenalidomide in Multiple Myeloma, sponsored by Hoffmann-La Roche. Recruiting at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Nov 5, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing iberdomide in Multiple Myeloma — 11 open to participants now, 24 under way, 3 of them phase 3. iberdomide · Multiple Myeloma.

Planned enrollment
5th of 27
200 · median 75
Started
2023
with 4 others
Phase 1/2
8 of 27
3 open now
Primary completion
2028-07
later than 15 of 23 live
Registered
15th of 27
by date

Among the 27 studies testing iberdomide in Multiple Myeloma, this one is the 5th largest by planned enrollment, is one of 5 that started in 2023, is one of 8 in phase 1/2, reaches primary completion later than 15 of the 23 other live ones, and was the 15th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

11 of the 27 studies testing iberdomide in Multiple Myeloma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iberdomide

iberdomide: first FDA approval 2026 (ZENBEXUS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing iberdomide in Multiple Myeloma, or all of them as a file.
02

Study summary

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Read the detailed description

Cevos + Len substudy(SS) 2 (DIRAC):

This substudy will explore the combination of cevostamab and lenalidomide as post-transplant maintenance therapy in participants with MM with high-risk cytogenetic features who experienced at least a partial response (PR) after induction.

Cevostamab + Iberdomide SS4 (CHAWLA):

This substudy will evaluate the safety, tolerability, PK, and pharmacodynamics of the combination of cevostamab and iberdomide in participants with R/R MM who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with MM per International Myeloma Working Group (IMWG) criteria
  • Performance Status of 0, or 1, or 2
  • Resolution of AEs from prior anti-cancer therapy to Grade \<=1
  • Agreement to undergo scheduled assessments and procedures

Additional Inclusion Criteria for SS2:

  • Completion of planned induction therapy and achievement of at least a partial response (PR)
  • Stem Cell Transplant (SCT) within 100 days prior to first study treatment and the absence of progressive disease
  • Cytogenetic high-risk features at diagnosis
  • Treatment with any medicinal products, systemic cancer therapies, immunotherapies received previously in CO43923 (any arms) within 5 half-lives or 3 weeks whichever is the shortest
  • Agreement to comply with all local requirements of the lenalidomide risk minimization plan, which includes the global pregnancy prevention program
  • For female participants of : agreement to remain abstinent (refrain from heterosexual intercourse) or use
  • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom even if they have had a prior vasectomy, and agreement to refrain from donating sperm

Additional Inclusion Criteria for SS4:

  • Previously exposed to at least a PI, an IMiD, and an anti-CD38 antibody for the treatment of R/R MM for whom no suitable SOC therapy options are available

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with protocol-mandated hospitalization and procedures
  • History of confirmed progressive multifocal leukoencephalopathy
  • History of other within 2 years prior to screening
  • Current or past history of central nervous system (CNS) disease
  • Significant cardiovascular disease that may limit a participant's ability to adequately respond to a CRS event
  • Symptomatic active pulmonary disease or requiring supplemental oxygen
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection requiring treatment with IV antibiotics where the last dose of IV antibiotics was given within 14 days prior to first study treatment
  • Known or suspected chronic active Epstein-Barr virus (EBV) infection
  • Positive serologic or PCR test results for acute or chronic virus (HBV) infection
  • Acute or chronic virus (HCV) infection
  • Known history of seropositivity
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation that such a live, attenuated vaccine will be required during the study
  • Any medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results

Additional Exclusion Criteria for SS2:

  • reactions to lenalidomide or other immunomodulatory drugs
  • Harbor lesions at proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
  • Prior treatment with any medicinal product, systemic cancer therapy, or immunotherapies in any arm of study CO43923 within 5 half-lives or 3 weeks, whichever is shorter
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antimicrobials where the last dose of IV antimicrobial was given within 14 days prior to first study treatment
  • History of erythema multiforme, Grade >=3 rash, or blistering following prior treatment with immunomodulatory derivatives
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment Exlcusion Criteria Applicable to SS2 and SS4
  • History of disease
  • Known history of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • Received a cumulative dose of equivalent to >=140 mg of prednisone within the 14-day period before the first dose of the study drug (does not include pretreatment medication)
  • Active symptomatic COVID-19 infection at study enrollment or requiring treatment with IV antiviral where the last dose of IV antiviral treatment was given within 14 days prior to first study treatment. Participants with active COVID-19 infection must have clinical recovery and two negative antigen tests at least 24 hours apart prior to first study treatment.
  • Positive and quantifiable EBV PCR or CMV PCR prior to first study treatment

Additional Exclusion Criteria for SS4:

  • Treatment with any investigational medicinal products, systemic cancer therapies, immunotherapies within 5 half-lives or 12 weeks before starting pre-phase
  • History of anaphylaxis or hypersensitivity, including >=Grade 3 rash, during prior treatment with IMiDs, dexamethasone, any CELMoDs, or the contained in the formulations
  • Known anaphylaxis, allergies, hypersensitivity, or intolerance to boron or mannitol, hyaluronidase, sorbitol, corticosteroids, monoclonal antibodies (or recombinant antibody-related fusion proteins), or human proteins, CRBN modulating agents or their excipients, or known sensitivity to mammalian-derived products
  • Administration of strong modulators; administration of proton-pump inhibitors within 2 weeks of starting study treatment
  • Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
  • Concurrent administration of a strong inhibitor, modulator or inducer of cytochrome P450 (CYP3A4/5) (including within 14 days of initiating study treatment)
  • History of malignancies, other than MM, unless the subject has been free of the disease for >=5 years
  • Peripheral neuropathy >Grade 2
  • Prior treatment with cevostamab or another agent targeting FcRH5 or iberdomide
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
  • History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug rash with eosinophilia and systemic symptoms
  • Treatment with systemic medications
  • Prior treatment with CAR T-cell therapy (autologous or allogeneic) within 12 weeks before starting pre-phase
  • SCT within 100 days prior to starting pre-phase
  • Prior allogeneic SCT
  • Plasmacytoma in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Substudy 2: Dose Escalation and Expansion

    In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on Day(D)1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 and D15 for cycles 1-6 and D1 of cycle 7 onwards. Each cycle is 28 days. Lenalidomide will be administered by mouth (PO) on a 28-day cycle. During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Lenalidomide will be administered PO on a 28-day cycle. Enrollment for Substudy 2 has closed.

    Drug: Cevostamab · Drug: Lenalidomide · Drug: Tocilizumab

  • Experimental
    Substudy 4: Dose Escalation and Expansion

    In the pre-phase, participants will receive 2 step-up doses and a target dose of cevostamab. The step-up dose will be given on D1 and D4. The target dose will be given on D8. Subsequently the target dose will be administered on D1 of each cycle, every 3 weeks (Q3W). Each cycle is 21 days. Iberdomide will be administered PO on a 21-day cycle. During the dose expansion phase, cevostamab will be administered following the same dosing schedule as the dose escalation phase. The target dose will be determined after the escalation phase. Iberdomide will be administered PO on a 21-day cycle.

    Drug: Cevostamab · Drug: Tocilizumab · Drug: Iberdomide · Drug: Dexamethasone

Interventions

  • Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles. Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

  • Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.

  • Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

  • Iberdomide will be administered PO on days 1-14 of a 21-day cycle.

  • Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.

06

What researchers measure

Primary outcomes

  1. Stage 1: Percentage of Participants with Adverse Events (AEs)

    Time frame: Baseline up to approximately 5 years

  2. Stage 2: Objective Response Rate (ORR)

    Time frame: Baseline up to approximately 5 years

  3. Stage 2: Complete Response (CR) or Stringent Complete Response (sCR) Rate

    Time frame: Baseline up to approximately 5 years

  4. Stage 2: Rate of Very Good Partial Response (VGPR) or Better

    Time frame: Baseline up to approximately 5 years

  5. Stage 2: Progression-free Survival (PFS)

    Time frame: Baseline up to approximately 5 years

  6. Stage 2: Overall Survival (OS)

    Time frame: Baseline up to approximately 5 years

Secondary outcomes

  1. Stage 1: Conversion to a Better Response

    Time frame: Baseline up to approximately 5 years

  2. Stage 1: PFS

    Time frame: Baseline up to approximately 5 years

  3. Stages 1 and 2: Duration of Response (DOR)

    Time frame: Baseline up to approximately 5 years

  4. Stage 1: OS

    Time frame: Baseline up to approximately 5 years

  5. Stages 1 and 2: Minimal Residual Disease (MRD) Negativity Rate

    Time frame: Baseline up to approximately 5 years

  6. Stage 1: ORR

    Time frame: Baseline up to approximately 5 years

  7. Stage 1: CR or sCR Rate

    Time frame: Baseline up to approximately 5 years

  8. Stage 1: Rate of VGPR or Better

    Time frame: Baseline up to approximately 5 years

  9. Stage 2: Stage 1: Percentage of Participants with AEs

    Time frame: Baseline up to approximately 5 years

  10. Stages 1 and 2: Time to First Response (for Participants who Achieve a Response of PR or Better)

    Time frame: Baseline up to approximately 5 years

  11. Stages 1 and 2: Time to Best Response (for Participants who Achieve a Response of PR or Better)

    Time frame: Baseline up to approximately 5 years

  12. Stages 1 and 2: Maximum Concentration Observed (Cmax)

    Time frame: Baseline up to approximately 5 years

  13. Stages 1 and 2: Minimum Concentration under Steady-State Conditions within a Dosing Interval (Cmin)

    Time frame: Baseline up to approximately 5 years

  14. Stages 1 and 2: Time to Maximum Concentration (Tmax)

    Time frame: Baseline up to approximately 5 years

  15. Stages 1 and 2: Area under the Concentration-Time Curve (AUC)

    Time frame: Baseline up to approximately 5 years

  16. Stages 1 and 2: Total Clearance of Drug (CL)

    Time frame: Baseline up to approximately 5 years

  17. Stages 1 and 2: Volume of Distribution at Steady State

    Time frame: Baseline up to approximately 5 years

  18. Stages 1 and 2: Terminal half-life

    Time frame: Baseline up to approximately 5 years

07

Study locations

14 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2028, 56 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 56 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 18, 2022
StartActual
Nov 14, 2023
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Poland)
  • Uniwersyteckie Centrum Kliniczne · Gda?sk, Poland
  • Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie · Olsztyn, Poland
Show 2 removed
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
  • Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie · Olsztyn, Poland
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Poland)
    • Uniwersyteckie Centrum Kliniczne · Gda?sk, Poland
    • Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji z Warminsko-Mazurskim Centrum Onkologii w Olsztynie · Olsztyn, Poland
    Show 2 removed
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    • Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie · Olsztyn, Poland
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05583617
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Nov 14, 2023
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: CO43923 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iberdomide

Start the discussion